Venous thrombosis and conjugated equine estrogen in women without a uterus.

BACKGROUND: Postmenopausal hormone therapy has been associated with a 2- to 3-fold increased risk of venous thromboembolism (VT) (including deep vein thrombosis and pulmonary embolism) in observational studies and secondary prevention clinical trials. Clinical trial data on the effects of estrogen alone on VT are limited. METHODS: The Women's Health Initiative estrogen trial enrolled 10 739 women aged 50 to 79 years without a uterus. Participants were randomly assigned to receive conjugated equine estrogen (0.625 mg/d) or placebo. RESULTS: During a mean of 7.1 years, VT occurred in 111 women randomly assigned to receive estrogen (3.0 per 1000 person-years) and 86 randomly assigned to receive placebo (2.2 per 1000 person-years; hazard ratio, 1.32; 95% confidence interval, 0.99-1.75). Deep venous thrombosis was reported in 85 women randomly assigned to receive estrogen (2.3 per 1000 person-years) and 59 randomly assigned to receive placebo (1.5 per 1000 person-years; hazard ratio, 1.47; 95% confidence interval, 1.06-2.06). The VT risk was highest in the first 2 years. There were no significant interactions between estrogen use and age, body mass index, or most other VT risk factors. Comparison of Women's Health Initiative VT findings for estrogen and previous Women's Health Initiative findings for estrogen plus progestin showed that the hazard ratios for estrogen plus progestin were significantly higher than those for estrogen alone (P = .03), even after adjusting for VT risk factors. CONCLUSION: An early increased VT risk is associated with use of estrogen, especially within the first 2 years, but this risk increase is less than that for estrogen plus progestin.

Predictors of success with methotrexate treatment of tubal ectopic pregnancy at Grady Memorial Hospital.

OBJECTIVE: The purpose of this study was to determine our institutional success rate with single-dose intramuscular methotrexate therapy for the treatment of ectopic pregnancy and to identify predictors of treatment outcome. STUDY DESIGN: This was a retrospective review of consecutive patients who were treated with methotrexate from January 2000 until April 2002. Successful treatment was defined as the resolution of the ectopic pregnancy without surgical intervention. RESULTS: Our overall success rate was 85% (69/81 patients). The median pretreatment serum beta-human chorionic gonadotropin level was lower in those women in whom treatment was successful compared with those women with treatment failure (793 vs 3804 mIU/mL, P <.002). The presence of a yolk sac that was visualized on vaginal ultrasonography was the only significant predictor of treatment failure (adjusted odds ratio, 19.3; P <.002). CONCLUSION: Our institutional success rate (85%) with methotrexate for treatment of tubal ectopic pregnancy is comparable with other published results. However, a finding unique to this study was that visualization of a yolk sac was a risk factor for failure.

An investigation of unexplained infant deaths in houses contaminated with methyl parathion.

In Lorain County, Ohio, unexplained infant deaths in homes sprayed with methyl parathion (MP), an organophosphate (OP) pesticide, prompted an investigation to determine whether infants living in treated homes are at higher risk for unexplained death. A case was defined as any death of an infant (12 months of age) in Lorain County between 1 January 1990 and 31 December 1994, attributed to sudden infant death syndrome (SIDS) or other unknown natural causes. For each case infant, birth certificate data were used to identify two control infants matched with regard to date of birth, sex, city of residence, and maternal race and educational level. Wipe samples from the home address listed on the birth certificate of control infants or the death certificate of case infants were analyzed for MP. Birth certificates provided additional risk factor information. The relationship between MP contamination and unexplained death was analyzed by exact conditional logistic regression. Wipe samples were collected from the residences of 34 case infants and 72 control infants. MP (>0.02 mg/100 cm2) was detected in five homes, three of which had been occupied by case infants. Case infants were 4.6 times more likely than control infants to have lived in MP-treated homes, but the confidence interval (CI) was wide (95% CI: 0.2, 274.7) and included 1. Maternal smoking, young maternal age, and the presence of other siblings in the family were each independently predictive of case status. In a multivariate model adjusting for these other variables and the matching variables, the estimated risk associated with MP exposure was 13.0 (95% CI: 0.2, 2,685.0). Although this association was not statistically significant and should be interpreted cautiously, it suggests an increased risk for unexplained death among infants living in MP-contaminated homes. The relationship between children's health and exposure to OP pesticides including MP should be evaluated further.